Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection

AIDS

Volumn 12, Issue 14, 1998, Pages 1833-1844

  Giorgi, Janis V ^a,c   Majchrowicz, Martin A ^a,b   Johnson, Timothy D ^a   Hultin, Patricia ^a   Matud, Jose ^a   Detels, Roger ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MediSolutions   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immune reconstitution; Lymphocyte subsets; Protease inhibitors

Indexed keywords

CD28 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; LAMIVUDINE; MONOCLONAL ANTIBODY; PADGEM PROTEIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOFLUORESCENCE; LYMPHOCYTE SUBPOPULATION; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS REPLICATION;

EID: 0032188878     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199814000-00015     Document Type: Article

References (49)

1. Giorgi JV: Phenotype and function of T tells in HIV disease. In Immunology of HIV Infection. Edited by Gupta S, New York: Plenum Press; 1996:181-199.
2. Kelleher AD, Zaunders ACJ, Cooper DA: Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996, 173:321-329.
3. Autran B, Carcelain G, Li TS, et al.: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
4. Pakker NG, Notermans DW, de Boer R, et al.: Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998, 4:208-214.
5. Lederman M, Connick E, Landay A, et al.: Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of Clinical Trials Group Protocol 315. J Infect Dis 1998, 178:70-79.
6. Fauci AS, Schnittman SM, Poli G, Koenig S, Pantaleo G: Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection. Ann Intern Med 1991, 114:678-692.
7. Giorgi JV: Characterization of T lymphocyte subset alterations by flow cytometry in HIV disease. Ann NY Acad Sci 1993, 677:126-137.
8. Roederer M, Dubs JC, Anderson MT, Raju PA, Herzenberg LA, Herzenberg LA: CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest 1995, 95:2061-2066.
9. Lewis DE, Tang DSN, Adu-Oppong A, Schober W, Rodgers JR: Anergy and apoptosis in CD8+ T cells from HIV-infected persons. J Immunol 1994, 153:412-420.
10. Ho H-N, Hultin LE, Mitsuyasu RL, et al.: Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens. J Immunol 1993, 150:3070-3079.
11. Giorgi JV, Kesson AM, Chou C-C: Immunodeficiency and infectious diseases. In Manual of Clinical Laboratory Immunology. Edited by Rose NR, de Macario EC, Fahey JL, Friedman H, Penn GM, Washington, DC: American Society of Microbiology; 1992:174-181.
12. Bass HZ, Hardy WD, Mitsuyasu RT, Wang Y-X, Cumberland W, Fabey JL: Eleven lymphoid phenotypic markers in HIV infection: selective changes induced by zidovudine treatment. J Acquir Immune Defic Syndr 1992, 5:890-897.
13. Giorgi JV, Boumsell L, Autran B: Reactivity of workshop T-cell section mAb with circulating CD4+ and CD8+ T cells in HIV disease and following in vitro activation. In Leucocyte Typing V: White Cell Differentiation Antigens. Edited by Schlossman SF, Boumsell L, Gilks W, et al. Oxford: Oxford University Press; 1995:446-461.
14. Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessey K, Detels R: Elevated levels of CD38 + CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. J Acquir Immune Defic Syndr 1993, 6:904-912.
15. Giorgi JV, Ho H-N, Hirji K, et al.: CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR + CD38-CD8+ cells is associated with subsequent stable CD4+ cell levels. J Infect Dis 1994, 170:775-781.
16. Liu Z, Cumberland WG, Hultin LE, Kaplan AH, Detels R, Giorgi JV: CD8+ T lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 18:332-340.
17. Caruso A, Cantalamessa A, Licenziati S, et al.: Expression of CD28 on CD8+ and CD4+ lymphocytes during HIV infection. Scand J Immunol 1994, 40:485-490.
18. Brinchmann JE, Dobloug JH, Heger BH, Haaheim LL, Sannes M, Egeland T: Expression of costimulatory molecule CD28 on T cells in human immunodeficiency virus type 1 infection: functional and clinical correlations. J Infect Dis 1994, 169:730-738.
19. Oyaizu N, Pahwa S: Role of apoptosis in HIV disease pathogenesis. J Clin Immunol 1995, 15:217-231.
20. Janossy G, Borthwick N, Lomnitzer R, et al.: Lymphocyte activation in HIV-1 infection. I. Predominant proliferative defects among CD45RO+ cells of the CD4 and CD8 lineages. AIDS 1991, 7:613-624.
21. Prince HE, Jensen ER: Three-color cytofluorometric analysis of CD8 cell subsets in HIV-1 infection. J Acquir Immune Defic Syndr 1991, 4:1227-1232.
22. Kestens L, Vanham C, Gigase P, et al.: Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection. AIDS 1992, 6:793-797.
23. Giorgi JV, Detels R: T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS Cohort Study. Clin Immunol Immunopathol 1989, 52:10-18.
24. Bouscarat F, Levacher-Clergeot M, Dazza M-C, et al.: Correlation of CD8 lymphocyte activation with cellular viremia and plasma HIV RNA levels in asymptomatic patient infected by human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1996, 12:17-24.
25. Lynne JE, Schmid J, Matud JL, et al.: Major expansions of select CD8+ subsets in acute EBV infection: comparison with chronic HIV disease. J Infect Dis 1998, 177:1083-1087.
26. Ferbas J, Kaplan AH, Hausner MA, et al.: Virus burden in long-term survivors of human immunodeficiency virus (HIV) infection is a determinant of anti-HIV CD8+ lymphocyte activity. J Infect Dis 1995, 172:329-339.
27. Wang ECY, Taylor-Wiedman J, Perera P, Fisher J, Borysiewicz IK: Subsets of CD8+ , CD57+ cells in normal, healthy individuals: correlation with human cytomegalovirus (HCMV) carrier status, phenotype and functional analyses. Clin Exp Immunol 1993, 94:297-305.
28. Posnett DN, Sinha R, Kabak S, Russo C: Clonal populations of T cells in normal elderly humans: the T cell equivalent to 'benign monoclonal gammapathy'. J Exp Med 1994, 179:609-618.
29. Serrano D, Monteiro J, Allen SL, et al.: Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia. J Immunol 1947, 158:1482-1489.
30. Giorgi JV, Hausner MA, Hultin LE: Detailed immunophenotype of CD8+ memory CTL against HIV-1 with respect to expression of CD45RA/RO, CD62L and CD28 antigens. Immunol Lett 1998 (in press).
31. Monteiro I, Batliwalla FM, Ostrer H, Gregersen PK: Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts. J Immunol 1996, 156:3587-3590.
32. Effros RB, Allsopp R, Chiu C-P, et al.: Shortened telomeres in the expanded CD28-CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS 1996, 10:F17-F22.
33. McCloskey TW, Oyaizu N, Kaplan M, Pahwa S: Expression of the Fas antigen in patients infected with human immunodeficiency virus. Cytometry 1993, 22:111-114.
34. Fahey JL, Prince H, Weaver M, et al.: Quantitative changes in T helper or T suppressor cytotoxic lymphocyte subsets that distinguish acquired immune deficiency syndrome from other immune subset disorders. Am J Med 1984, 76:93-100.
35. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr: The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987, 126:310-318.
36. Chmiel JS, Detels R, Kaslow RA, et al.: Factors associated with prevalent human immunodeficiency virus (HIV) infection in the Multicenter AIDS Cohort Study. Am J Epidemiol 1987, 126:568-577.
37. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S: Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994, 32:292-300.
38. Hultin L, Matud J, Giorgi JV: Quantitation of CD38 activation antigen expression on CD8+ T cells in HIV-1 infection using CD4 expression on CD4+ T lymphocytes as a biological calibrator. Cytometry 1998 (in press).
39. Lehman EL: Nonparametrics: Statistical Methods Based on Ranks. San Francisco: Holden-Day, Inc.; 1975.
40. StatXact (Version 3.01) Boston: Cytel Software, Inc.; 1975.
41. Neter J, Wasserman W, Kutner MH: Applied Linear Statistical Models. Homewood (IL): Richard D, Irwin, Inc.; 1990:162.
42. Seber GAF: Linear Regression Analysis. New York: John Wiley & Sons, Inc.; 1977:127.
43. Efron B, Tibshirani RJ: An Introduction to the Bootstrap. New York: Chapman and Hall; 1993.
44. Detels R, English P, Visscher BR, et al.: Seroconversion, sexual activity, and condom use among 2915 HIV seronegative men followed for up to 2 years. J Acquir Immune Defic Syndr 1989, 2:77-83.
45. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV: Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the multicenter AIDS cohort study than CD4+ cell count, soluble immune activation markers or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:83-92.
46. Chou C-C, Gudeman V, O'Rourke S, et al.: Phenotypically defined memory CD4+ cells are not selectively decreased in chronic HIV disease. J Acquir Immune Defic Syndr 1994, 7:665-675.
47. Connors M, Kovacs JA, Krevat S, et al.: HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997, 3:533-540.
48. Lees O, Ramzaoui S, Gilbert D, et al.: The impaired in vitro production of interleukin-2 in HIV infection is negatively correlated to the number of circulating CD4+DR+ T cells and is reversed by allowing T cells to rest in culture: arguments for in vivo CD4+ T cell activation. Clin Immunol Immunopathol 1993, 67:185-191.
49. Mildvan D, Landay A, De Gruttola V, Machado SG, Kagan J: An approach to the validation of markers for use in AIDS clinical trials. Clin Infect Dis 1997, 24:764-774.